Personalized Breast Cancer Treatment

Mårten Fernö

PROJECTS

•  Prognostic and treatment predictive factors in breast cancer 
•  Prognostic factors for local recurrence and radioresistance  
•  Prognostic factors for metachronous contralateral breast cancer 
•  Tumor markers in serum and plasma 
•  Quality assurance 

Research at the Faculty of Medicine 

GROUP MEMBERS

•  Kristina Aaltonen, PhD; Post Doc
•  Sara Alkner, MD; PhD student
•  Sara Baker, MSc; Research Engineer
•  Pär-Ola Bendahl, PhD; Biostatistician
•  Gunilla Chebil, Senior Consultant Histopathology
•  Anna-Karin Falck, MD; PhD student
•  Dorthe Grabau, Senior Consultant Histopathology
•  Marie Klintman, MD; PhD student
•  Kristina Lövgren, BSc; Biomedical scientist
•  Ulrik Narbe, MD; PhD student
•  Carina Strand, MSc; PhD student/Biomedical scientist
•  Linda Werner Hartman, PhD; Biostatistician

NATIONAL AND INTERNATIONAL NETWORKS

•  EORTC PathoBiology Group
•  South Swedish Breast Cancer Group
•  Swedish Breast Cancer Group
•  Swedish Cancer Society Study Group “Prognostic and treatment predictive factors in breast cancer
•  SweQA-breast cancer
•  Scandinavian Breast Group

SELECTED PUBLICATIONS

Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat. 2012 Feb;131(3):939-47. Epub 2011 Nov 18.

Alkner S, Bendahl PO, Fernö M, Manjer J, Rydén L. Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer. 2011 Mar 30;11:114

Strand C, Ahlin C, Bendahl PO, Fjällskog ML, Hedenfalk I, Malmström P, Fernö M. Combination of the proliferation marker cyclin A, histological grade, and estrogen receptor status in a new variable with high prognostic impact in breast cancer. Breast Cancer Res Treat. 2012 Jan;131(1):33-40. Epub 2011 Feb 18.

Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A: Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol, 28(11):1813-1820 (2010).

Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M: Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Treat 2010, 120(2):491-8.

Klintman M, Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M: The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010, 23(2):251-9.

Alkner S, Bendahl PO, Grabau D, Lovgren K, Stal O, Ryden L, Ferno M: AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol 2010, 21(2):238-44.

Ryden L, Haglund M, Bendahl PO, Hatschek T, Kolaric A, Kovacs A, Olsson A, Olsson H, Strand C, Ferno M: Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol 2009, 48(6):860-6.

Niméus-Malmström E, Krogh M, Malmström P, Strand C, Fredriksson I, Karlsson P, Nordenskjöld B, Stål O, Ostberg G, Peterson C, Fernö M. Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surger, with or without postoperative radiotherapy. Breast Cancer Res. 2008;10(2):R34.

Brommesson, S., Jönsson, G., Strand, C., Grabau, D., Malmström, P., Ringnér, M., Fernö, M., Hedenfalk, I. Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC Clin Pathol 2008, 8, 6.